Yager J D, Zurlo J, Ni N
Department of Environmental Health Sciences, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205.
Proc Soc Exp Biol Med. 1991 Nov;198(2):667-74. doi: 10.3181/00379727-198-43305.
Epidemiological and experimental data strongly support a causal relationship between exposure to excessive levels of estrogens and the development of cancer in various tissues. In this paper, we have presented background information that shows a correlation between the prolonged use of oral contraceptives and the development of liver cancer. The clinical data supported the hypothesis that the estrogenic components of oral contraceptives were promoters of hepatocarcinogenesis, and the experimental evidence in support of this hypothesis and bearing on the mechanisms involved are also reviewed. The effects of estrogens on liver neoplasia and growth are: (i) synthetic steroidal estrogens are potent promoters of hepatocarcinogenesis in female rats; (ii) these estrogens stimulate liver growth at doses that are not hepatotoxic; (iii) the mechanisms by which the estrogens stimulate liver growth are indirect and include the enhancement of a serum/plasma growth factor, co-mitogenic effects which result in enhanced responsiveness of cultured hepatocytes to epidermal growth factor and decreased sensitivity of hepatocytes to growth inhibition by transforming growth factor-beta; (iv) the co-mitogenic effects of synthetic estrogens extend to endogenous estrogens and natural product estrogens; and (v) the co-mitogenic effects of estrogens for epidermal growth factor are associated with increased epidermal growth factor receptor protein levels caused by an increase in the half-life of the receptor protein. The synthetic estrogens also have weak "complete" carcinogenic activity in rat liver and strong complete carcinogenic activity in Syrian hamster kidney and Armenian hamster liver. Evidence from the literature is presented in support of a hypothesis that this process may involve indirect genotoxicity mediated through redox cycling and the formation of hydroxylated DNA bases. This process, together with the potent promoting activity of these estrogenic chemicals, may account for their complete carcinogenicity.
流行病学和实验数据有力地支持了接触过量雌激素与多种组织癌症发生之间的因果关系。在本文中,我们提供了背景信息,表明长期使用口服避孕药与肝癌发生之间存在关联。临床数据支持了这样的假设,即口服避孕药中的雌激素成分是肝癌发生的促进剂,同时也对支持这一假设及相关机制的实验证据进行了综述。雌激素对肝脏肿瘤形成和生长的影响包括:(i)合成甾体雌激素是雌性大鼠肝癌发生的强力促进剂;(ii)这些雌激素在非肝毒性剂量下刺激肝脏生长;(iii)雌激素刺激肝脏生长的机制是间接的,包括增强血清/血浆生长因子、协同促有丝分裂作用,这导致培养的肝细胞对表皮生长因子的反应性增强,以及肝细胞对转化生长因子-β抑制生长的敏感性降低;(iv)合成雌激素的协同促有丝分裂作用扩展到内源性雌激素和天然产物雌激素;(v)雌激素对表皮生长因子的协同促有丝分裂作用与受体蛋白半衰期延长导致的表皮生长因子受体蛋白水平增加有关。合成雌激素在大鼠肝脏中也具有较弱的“完全”致癌活性,在叙利亚仓鼠肾脏和亚美尼亚仓鼠肝脏中具有较强的完全致癌活性。文中呈现了文献证据以支持这样一个假设,即这个过程可能涉及通过氧化还原循环和羟基化DNA碱基形成介导的间接基因毒性。这个过程,连同这些雌激素化学物质的强力促进活性,可能解释了它们的完全致癌性。